[go: up one dir, main page]

AR095326A1 - Heterociclos tricíclicos como inhibidores de la proteína bet - Google Patents

Heterociclos tricíclicos como inhibidores de la proteína bet

Info

Publication number
AR095326A1
AR095326A1 ARP140101029A ARP140101029A AR095326A1 AR 095326 A1 AR095326 A1 AR 095326A1 AR P140101029 A ARP140101029 A AR P140101029A AR P140101029 A ARP140101029 A AR P140101029A AR 095326 A1 AR095326 A1 AR 095326A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
cycloalkyl
halo
independently selected
Prior art date
Application number
ARP140101029A
Other languages
English (en)
Inventor
D Rodgers James
P Combs Andrew
B Sparks Richard
P Jr Maduskuie Tomas
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR095326A1 publication Critical patent/AR095326A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, caracterizado porque: ⁻ ⁻ ⁻ ⁻ ⁻ representa un enlace sencillo o un enlace doble; L es CR⁹R⁹ᵃ, O, S, SO, o SO₂; Cy¹ es seleccionado de fenilo o un grupo heteroarilo de 5 - 6 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, en donde el fenilo o heteroarilo de 5 - 6 miembros Cy¹ es opcionalmente sustituido con 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹¹; R¹ y R² son seleccionados independientemente de H, halo, CN, OH, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, ORᵃ¹, SRᵃ¹, C(=O)Rᵇ¹, C(=O)NRᶜ¹Rᵈ¹, C(=O)ORᵃ¹, OC(=O)Rᵇ¹, OC(=O)NRᶜ¹Rᵈ¹, NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)Rᵇ¹, NRᶜ¹C(=O)NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)ORᵃ¹, S(=O)Rᵇ¹, S(=O)NRᶜ¹Rᵈ¹, S(=O)₂Rᵇ¹, NRᶜ¹S(=O)₂Rᵇ¹ y S(=O)₂NRᶜ¹Rᵈ¹, en donde el alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ de R¹ y R² son opcionalmente sustituidos con 1, 2, ó 3 grupos seleccionados independientemente de halo, CN, OH, ORᵃ¹, SRᵃ¹, C(=O)Rᵇ¹, C(=O)NRᶜ¹Rᵈ¹, C(=O)ORᵃ¹, OC(=O)Rᵇ¹, OC(=O)NRᶜ¹Rᵈ¹, NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)Rᵇ¹, NRᶜ¹C(=O)NRᶜ¹Rᵈ¹, NRᶜ¹C(=O)ORᵃ¹, S(=O)Rᵇ¹, S(=O)NRᶜ¹Rᵈ¹, S(=O)₂Rᵇ¹, NRᶜ¹S(=O)₂Rᵇ¹ y S(=O)₂NRᶜ¹Rᵈ¹; siempre que ni R¹ ni R² sean Cl, Br, I, CN, u OH cuando L es O ó S; alternativamente, R¹ y R² junto con el átomo de carbono al cual se unen se combinan para formar un grupo cicloalquilo C₃₋₇, en donde el grupo cicloalquilo es opcionalmente sustituido con 1, 2, 3, ó 4 grupos seleccionados independientemente de R²⁰; Cy³ es seleccionado de fenilo, cicloalquilo C₃₋₇, un grupo heteroarilo de 5 - 10 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 10 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el fenilo, cicloalquilo C₃₋₇, heteroarilo de 5 - 10 miembros, y heterocicloalquilo de 4 - 10 miembros de Cy³ es opcionalmente sustituido con 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹³, en donde un átomo de nitrógeno formador del anillo del grupo heteroarilo de 5 - 10 miembros o un átomo de nitrógeno formador del anillo del grupo heterocicloalquilo de 4 - 10 miembros es opcionalmente oxidado; R⁴ es H, C(=O)NR¹⁴ᵃR¹⁴ᵇ, C(=O)R¹⁴ᵃ, C(=O)OR¹⁴ᵃ, o alquilo C₁₋₆ opcionalmente sustituido por 1, 2, ó 3 sustituyentes seleccionados independientemente de halo, NR¹⁴ᵃR¹⁴ᵇ, OR¹⁴ᵃ, SR¹⁴ᵃ, CN, C(=O)R¹⁴ᵃ, C(=O)NR¹⁴ᵃR¹⁴ᵇ, C(=O)OR¹⁴ᵃ, OC(=O)R¹⁴ᵇ, OC(=O)NR¹⁴ᵃR¹⁴ᵇ, NR¹⁴ᵃC(=O)R¹⁴ᵇ, NR¹⁴ᵃC(=O)NR¹⁴ᵃR¹⁴ᵇ, NR¹⁴ᵃC(=O)OR¹⁴ᵇ, S(=O)R¹⁴ᵃ, S(=O)NR¹⁴ᵃR¹⁴ᵇ, S(=O)R¹⁴ᵃ, NR¹⁴ᵃS(=O)₂R¹⁴ᵇ, y S(=O)₂NR¹⁴ᵃR¹⁴ᵇ; R⁵ es seleccionado de =O y =S cuando C⁻ ⁻ ⁻ ⁻N es un enlace sencillo, alternativamente, cuando C⁻ ⁻ ⁻ ⁻N es un enlace doble entonces R⁵ es seleccionado de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, NR¹⁵ᵃR¹⁵ᵇ, -C(=O)NR¹⁵ᵃR¹⁵ᵇ, -C(=O)OR¹⁵ᵃ, fenilo, cicloalquilo C₃₋₇, grupo heteroarilo de 5 - 6 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 10 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el alquilo, fenilo, cicloalquilo C₃₋₇, heteroarilo de 5 - 6 miembros, y heterocicloalquilo de 4 - 10 miembros de R⁵ es opcionalmente sustituido por 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹⁵; R⁶ es seleccionado de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, y haloalquilo C₁₋₆, en donde el alquilo, alquenilo, y alquinilo de R⁶ son cada uno opcionalmente sustituidos por 1, 2, 3, ó 4 grupos seleccionados independientemente de R¹⁶; alternativamente, R⁶ es seleccionado de arilo C₆₋₁₀, cicloalquilo C₃₋₇, grupo heteroarilo de 5 - 10 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 7 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el arilo C₆₋₁₀, cicloalquilo C₃₋₇, heteroarilo de 5 - 10 miembros, y heterocicloalquilo de 4 - 7 miembros de R⁶ son cada uno opcionalmente sustituidos por 1, 2, 3, ó 4 grupos seleccionados independientemente de R²⁰; R⁷ es seleccionado de H, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, C(=O)NRᶜRᵈ, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, fenilo, cicloalquilo C₃₋₇, grupo heteroarilo de 5 - 6 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O y S, y un grupo heterocicloalquilo de 4 - 7 miembros que comprende carbono y 1, 2, ó 3 heteroátomos seleccionados de N, O y S, en donde el alquilo, alquenilo, alquinilo, fenilo, cicloalquilo, grupo heteroarilo de 5 - 6 miembros, y un grupo heterocicloalquilo de 4 - 7 miembros de R⁷ son opcionalmente sustituidos con 1, 2, ó 3 grupos seleccionados independientemente de R¹⁷; R⁸ es seleccionado de H, alquilo C₁₋₃, alquenilo C₂₋₃, alquinilo C₂₋₃, haloalquilo C₁₋₃, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, y C(=O)NRᶜRᵈ, en donde el alquilo C₁₋₃ de R⁸ es opcionalmente sustituido con 1, 2, ó 3 grupos seleccionados independientemente de R¹⁸; R⁹ y R⁹ᵃ son seleccionados independientemente de H, alquilo C₁₋₃, haloalquilo C₁₋₃, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, y C(=O)NRᶜRᵈ; R¹¹ independientemente en cada caso es seleccionado de H, alquilo C₁₋₃, haloalquilo C₁₋₃, halo, CN, ORᵃ, NRᶜRᵈ, SRᵇ, y C(=O)NRᶜRᵈ, en donde el alquilo de C₁₋₃ es opcionalmente sustituido por OH; R¹³ independientemente en cada caso es seleccionado de H, halo, CN, OH, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, ORᵃ³, SRᵃ³, C(=O)Rᵇ³, C(=O)NRᶜ³Rᵈ³, C(=O)ORᵃ³, OC(=O)Rᵇ³, OC(=O)NRᶜ³Rᵈ³, NRᶜ³Rᵈ³, NRᶜ³C(=O)Rᵇ³, NRᶜ³C(=O)NRᶜ³Rᵈ³, NRᶜ³C(=O)ORᵃ³, S(=O)Rᵇ³, S(=O)NRᶜ³Rᵈ³, S(=O)₂Rᵇ³, NRᶜ³S(=O)₂Rᵇ³ y S(=O)₂NRᶜ³Rᵈ³, en donde el alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ de R¹³ es opcionalmente sustituido con 1, 2, ó 3 grupos seleccionados independientemente de halo, CH, OH, ORᵃ³, SRᵃ³, C(=O)Rᵇ³, C(=O)NRᶜ³Rᵈ³, C(=O)ORᵃ³, OC(=O)Rᵇ³, OC(=O)NRᶜ³Rᵈ³, NRᶜ³Rᵈ³, NRᶜ³C(=O)Rᵇ³, NRᶜ³C(=O)NRᶜ³Rᵈ³, NRᶜ³C(=O)ORᵃ³, S(=O)Rᵇ³, S(=O)NRᶜ³Rᵈ³, S(=O)₂Rᵇ³, NRᶜ³S(=O)₂Rᵇ³ y S(=O)₂NRᶜ³Rᵈ³; R¹⁵ independientemente en cada caso es seleccionado de H, alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, halo, CN, ORᵃ⁵, SRᵃ⁵, C(=O)Rᵇ⁵, C(=O)NRᶜ⁵Rᵈ⁵, C(=O)ORᵃ⁵, OC(=O)Rᵇ⁵, OC(=O)NRᶜ⁵Rᵈ⁵, NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(=O)Rᵇ⁵, NRᶜ⁵C(=O)NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(=O)ORᵃ⁵, S(=O)Rᵇ⁵, S(=O)NRᶜ⁵Rᵈ⁵, S(=O)₂Rᵇ⁵, NRᶜ⁵S(=O)₂Rᵇ⁵, y S(=O)₂NRᶜ⁵Rᵈ⁵, en donde el alquilo C₁₋₆, cicloalquilo de C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, y heteroarilo de 5 - 6 miembros son cada uno opcionalmente sustituidos por 1, 2, ó 3 sustituyentes seleccionados independientemente de halo, CN, ORᵃ⁵, SRᵃ⁵, C(=O)Rᵇ⁵,
ARP140101029A 2013-03-15 2014-03-14 Heterociclos tricíclicos como inhibidores de la proteína bet AR095326A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361794812P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095326A1 true AR095326A1 (es) 2015-10-07

Family

ID=50639971

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101029A AR095326A1 (es) 2013-03-15 2014-03-14 Heterociclos tricíclicos como inhibidores de la proteína bet

Country Status (24)

Country Link
US (6) US9227985B2 (es)
EP (2) EP2970282B1 (es)
JP (3) JP6243003B2 (es)
KR (2) KR102216288B1 (es)
CN (2) CN105164131B (es)
AR (1) AR095326A1 (es)
AU (1) AU2014228175B2 (es)
BR (1) BR112015022942B1 (es)
CA (1) CA2903881C (es)
CL (1) CL2015002734A1 (es)
CR (1) CR20150513A (es)
EA (2) EA038494B1 (es)
EC (1) ECSP15043772A (es)
ES (2) ES2909778T3 (es)
IL (2) IL241158B (es)
MX (2) MX366703B (es)
NZ (1) NZ712453A (es)
PE (1) PE20151990A1 (es)
PH (2) PH12015502157A1 (es)
SG (2) SG11201506924YA (es)
TW (2) TWI719464B (es)
UA (1) UA119848C2 (es)
WO (1) WO2014143768A1 (es)
ZA (2) ZA201507255B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
TW201932456A (zh) 2013-01-15 2019-08-16 美商英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
HK1243021A1 (zh) 2014-10-14 2018-07-06 The Regents Of The University Of California 使用cdk9和brd4抑制剂来抑制炎症
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
CN105985282B (zh) * 2015-01-28 2020-12-08 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017042182A1 (en) * 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AR106520A1 (es) * 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
US20190040063A1 (en) * 2016-02-05 2019-02-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof
WO2017172914A1 (en) 2016-03-30 2017-10-05 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
PT3472157T (pt) 2016-06-20 2023-05-30 Incyte Corp Formas sólidas cristalinas de um inibidor bet
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US12171764B2 (en) * 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
JP7584802B2 (ja) * 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｓｔｉｎｇタンパク質アゴニスト
CN110879294A (zh) * 2018-09-05 2020-03-13 成都市第三人民医院 蛋白标志物在诊断肠易激综合征的产品中的用途和用于诊断肠易激综合征的试剂盒
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
US20210265016A1 (en) 2020-02-20 2021-08-26 Illumina, Inc. Data Compression for Artificial Intelligence-Based Base Calling
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202231282A (zh) * 2021-02-03 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 稠三環類細胞週期蛋白－依賴性激酶抑制劑及其製備方法和醫藥用途
CN117794546A (zh) * 2021-08-10 2024-03-29 葛兰素史密斯克莱有限责任公司 莫洛替尼组合疗法
CN113975278B (zh) * 2021-10-29 2023-04-07 中国科学院昆明动物研究所 溴隐亭在制备治疗非洲猪瘟的产品中的应用

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59170313A (ja) 1983-03-14 1984-09-26 Kurimoto Iron Works Ltd スクリ−ンゲ−ト
JPS6085739U (ja) 1983-11-18 1985-06-13 クラリオン株式会社 テ−プレコ−ダにおけるピンチロ−ラ装置
JPH0314566A (ja) * 1989-06-09 1991-01-23 Sankyo Co Ltd ベンズイミダゾール誘導体
US5244912A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
FR2710915B1 (fr) 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
GB9410469D0 (en) * 1994-05-25 1994-07-13 Erba Farmitalia Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation
FR2731708B1 (fr) * 1995-03-13 1997-04-30 Synthelabo Derives de piperidine, leur procede de preparation et leur application en therapeutique
FR2747678B1 (fr) 1996-04-22 1998-05-22 Synthelabo Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
DK1274430T3 (da) 2000-04-21 2006-02-13 Pharmacia & Upjohn Co Llc Cabergolin til behandling af fibromyalgi og kronisk trathedssyndrom
NZ522783A (en) 2000-06-28 2004-07-30 Smithkline Beecham P Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
FR2816619B1 (fr) 2000-11-15 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
ES2233671T3 (es) * 2000-08-08 2005-06-16 Sanofi-Aventis Derivados de benzimidazol, su preparacion y aplicacion en terapeutica.
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
NZ539952A (en) * 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
EP1462103A1 (en) 2003-03-25 2004-09-29 Faust Pharmaceuticals NO donors, combination products and uses as modulators of neurotransmitter release
EP1719761A4 (en) 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co NEW HETEROCYCLIC CONNECTION
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DE102005011058A1 (de) * 2005-03-10 2006-09-14 Merck Patent Gmbh Substituierte Tetrahydro-pyrrolo-chinolinderivate
US20070032469A1 (en) 2005-08-05 2007-02-08 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
US8975259B2 (en) 2007-04-27 2015-03-10 University Of Rochester Compositions and methods for inhibiting G protein signaling
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009020559A2 (en) 2007-08-03 2009-02-12 The J. David Gladstone Institutes Agents that inhibit p-tefb interactions and methods of use thereof
EP2239264A4 (en) * 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
DE102008052618A1 (de) 2008-10-21 2010-04-22 Henkel Ag & Co. Kgaa Tricyclische Aldehyde und C,H-acide Verbindungen
WO2010111626A2 (en) 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
TW201105681A (en) * 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201103941A (en) 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US9360482B2 (en) 2009-11-05 2016-06-07 Glaxosmithkline Llc Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4
AU2010314395B2 (en) 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2779423C (en) 2009-11-05 2018-08-14 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
KR20130069640A (ko) 2010-04-23 2013-06-26 키네타, 인크. 항-바이러스 화합물
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
JP6022442B2 (ja) 2010-05-14 2016-11-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 男性用避妊組成物および使用方法
CN103037865B (zh) 2010-05-14 2014-10-29 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的化合物
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
KR20130116358A (ko) 2011-02-09 2013-10-23 에프. 호프만-라 로슈 아게 Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
AU2012220620A1 (en) 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
WO2012126901A1 (en) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US20150197497A1 (en) 2011-06-24 2015-07-16 Dana-Farber Cancer Institute, Inc. Selective inhibitors of histone deacetylase isoform 6 and methods thereof
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
JP2014524409A (ja) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｈｉｖの治療のための組成物および方法
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
CN105017151B (zh) 2011-08-31 2019-04-02 大塚制药株式会社 喹诺酮化合物
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
EP2757887B1 (en) 2011-09-22 2017-04-26 VIIV Healthcare UK Limited Pyrrolopyridinone compounds and methods for treating hiv
WO2013044511A1 (zh) 2011-09-30 2013-04-04 沈阳蓝桑医药生物技术研发有限公司 含有瑞利格内酯的药物组合物及其应用
WO2013060636A1 (en) 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SI2773354T1 (sl) 2011-11-01 2019-08-30 Resverlogix Corp. Peroralne formulacije s takojšnjim sproščanjem za substituirane kinazolinone
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20150133434A1 (en) 2012-03-28 2015-05-14 The J. David Gladstone Institutes Compositions and Methods for Reactivating Latent Immunodeficiency Virus
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281396A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
CN104334526A (zh) 2012-04-20 2015-02-04 艾伯维公司 异吲哚酮衍生物
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
MX2014015156A (es) 2012-06-12 2015-08-06 Abbvie Inc Derivados de piridinona y piridazinona.
MX2014015986A (es) 2012-06-25 2016-02-11 Oncoethix Gmbh Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
US9610332B2 (en) 2012-07-18 2017-04-04 Massachusetts Institute Of Technology Compositions and methods for modulating BRD4 bioactivity
KR20150042231A (ko) 2012-08-16 2015-04-20 글락소스미스클라인 엘엘씨 소세포폐암을 치료하기 위한 벤조디아제핀
EA201590356A1 (ru) 2012-08-16 2015-07-30 Байер Фарма Акциенгезельшафт 2,3-бензодиазепины
EP2900221B1 (en) 2012-09-28 2019-03-06 Oncoethix GmbH Pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2014048945A1 (de) 2012-09-28 2014-04-03 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
DK2917181T3 (da) 2012-11-09 2020-01-13 Medicines For Malaria Venture Mmv Heteroarylderivater og anvendelser deraf
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
ES2625945T3 (es) 2012-11-14 2017-07-21 Glaxosmithkline Llc Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
EP2935261A1 (de) 2012-12-20 2015-10-28 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydrochinoxalinone
CN105229002A (zh) 2012-12-20 2016-01-06 拜耳医药股份有限公司 抑制bet蛋白的二氢吡啶并吡嗪酮
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
WO2014128655A1 (en) 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
US10053454B2 (en) 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CN105377851B (zh) 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
JP2016516701A (ja) 2013-03-11 2016-06-09 アッヴィ・インコーポレイテッド 縮合四環系ブロモドメイン阻害剤
JP2016512524A (ja) 2013-03-11 2016-04-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
JP2016512543A (ja) 2013-03-12 2016-04-28 アッヴィ・インコーポレイテッド ジヒドロ−ピロロピリジノンブロモドメイン阻害剤
EP2970330B1 (en) 2013-03-12 2019-04-17 AbbVie Inc. Tetracyclic bromodomain inhibitors
BR112015022551A2 (pt) 2013-03-12 2017-07-18 Abbvie Inc inibidores de amido pirrol
HRP20182179T1 (hr) 2013-03-14 2019-02-22 Glaxosmithkline Intellectual Property (No. 2) Limited 2,3-disupstituirani 1-acil-4-amino-1,2,3,4-tetrahidrokonolin derivati i njihova uporaba kao inhibitora bromodomena
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
AU2014230816B9 (en) 2013-03-14 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
HK1222793A1 (zh) 2013-03-14 2017-07-14 康威基内有限公司 用於抑制含布罗莫结构域的蛋白质的方法和组合物
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
PT2970265T (pt) 2013-03-15 2018-10-23 Plexxikon Inc Compostos heterocíclicos e suas utilizações
US20160039842A1 (en) 2013-03-15 2016-02-11 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
JP6453845B2 (ja) 2013-03-27 2019-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体
EP2978757B1 (en) 2013-03-27 2017-02-08 Boehringer Ingelheim International GmbH Indolinone analogues as brd4 inhibitors
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
MX366623B (es) 2013-04-26 2019-07-16 Beigene Ltd 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas.
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
PL3004112T3 (pl) 2013-05-28 2018-02-28 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
ITMI20130991A1 (it) 2013-06-17 2014-12-18 Industrie De Nora Spa Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse.
CA2915419A1 (en) 2013-06-17 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted phenyl-2,3-benzodiazepines
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
MX2015017963A (es) 2013-06-28 2016-11-10 Abbvie Inc Inhibidores de bromodominio.
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
AU2014292193B2 (en) 2013-07-16 2018-04-26 Basf Se Herbicidal azines
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
KR101672096B1 (ko) 2013-09-30 2016-11-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
EP3640241B1 (en) 2013-10-18 2022-09-28 Celgene Quanticel Research, Inc. Bromodomain inhibitors
WO2015081246A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9428514B2 (en) 2013-12-09 2016-08-30 Abbvie Inc. Bromodomain inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
PL3092227T3 (pl) 2014-01-09 2018-12-31 Orion Corporation Bicykliczne pochodne heterocykliczne jako inhibitory bromodomeny
AU2015222887B2 (en) 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
MY195742A (en) 2014-04-23 2023-02-08 Takeda Pharmaceuticals Co Isoindoline-1-One Derivatives as Cholinergic Muscarinic M1 Receptor Positive Alloesteric Modulator Activity for the Treatment of Alzheimers Disease
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
CN106232595B (zh) 2014-04-23 2020-01-14 巴斯夫欧洲公司 作为除草剂的二氨基三嗪化合物
MX2016014299A (es) 2014-05-02 2017-01-27 Oncoethix Gmbh Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina.
US9956228B2 (en) 2014-05-02 2018-05-01 Oncoethix Gmbh Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
WO2015169953A1 (en) 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating glioma using thienotriazolodiazepine compounds
KR20170002610A (ko) 2014-05-08 2017-01-06 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 삼중 음성 유방암의 치료 방법
US10065951B2 (en) 2014-05-30 2018-09-04 Icahn School Of Medicine At Mount Sinai Small molecule transcription modulators of bromodomains
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
CA2965517C (en) 2014-10-24 2023-05-02 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
US10259809B2 (en) 2015-02-03 2019-04-16 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
WO2016186453A1 (en) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
MX2017015256A (es) 2015-05-29 2018-02-19 Shionogi & Co Derivados triciclicos que contienen nitrogeno que tienen actividad inhibidora de la replicacion del virus de inmunodeficiencia adquirida (vih).
CN105039258B (zh) 2015-07-03 2018-04-17 北京大学 将非神经元细胞重编程为神经元样细胞的方法和组合物
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
CN105254635A (zh) 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
US20170127985A1 (en) 2015-11-11 2017-05-11 Medtronic Minimed, Inc. Sensor set
US20190263799A1 (en) 2015-12-14 2019-08-29 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
US20190040063A1 (en) 2016-02-05 2019-02-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof
PT3472157T (pt) 2016-06-20 2023-05-30 Incyte Corp Formas sólidas cristalinas de um inibidor bet
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用

Also Published As

Publication number Publication date
KR102216288B1 (ko) 2021-02-18
EA201992712A3 (ru) 2020-05-31
JP2016513716A (ja) 2016-05-16
CN109593096A (zh) 2019-04-09
KR20210021090A (ko) 2021-02-24
WO2014143768A1 (en) 2014-09-18
CL2015002734A1 (es) 2016-03-28
EP3581576A1 (en) 2019-12-18
IL267609A (en) 2019-08-29
NZ712453A (en) 2020-06-26
MX366703B (es) 2019-07-22
JP2019142973A (ja) 2019-08-29
CN105164131A (zh) 2015-12-16
US9938294B2 (en) 2018-04-10
US10464947B2 (en) 2019-11-05
BR112015022942A2 (pt) 2017-07-18
ZA202001242B (en) 2021-08-25
EA038494B1 (ru) 2021-09-07
US20200131195A1 (en) 2020-04-30
TW201512198A (zh) 2015-04-01
CA2903881A1 (en) 2014-09-18
MX2019008521A (es) 2019-10-30
EP2970282A1 (en) 2016-01-20
US10919912B2 (en) 2021-02-16
EA035469B1 (ru) 2020-06-22
BR112015022942B1 (pt) 2022-02-22
ECSP15043772A (es) 2017-08-31
TWI667238B (zh) 2019-08-01
TW201930303A (zh) 2019-08-01
JP6243003B2 (ja) 2017-12-06
KR102355670B1 (ko) 2022-02-08
EP2970282B1 (en) 2019-08-21
ES2755827T3 (es) 2020-04-23
PH12019502318A1 (en) 2020-12-07
JP2018008958A (ja) 2018-01-18
TWI719464B (zh) 2021-02-21
US9624241B2 (en) 2017-04-18
CA2903881C (en) 2021-05-18
PH12015502157A1 (en) 2016-01-25
UA119848C2 (uk) 2019-08-27
US20160046650A1 (en) 2016-02-18
IL267609B (en) 2020-07-30
KR20150136497A (ko) 2015-12-07
CR20150513A (es) 2016-01-04
US20210188872A1 (en) 2021-06-24
EP3581576B1 (en) 2022-01-26
IL241158B (en) 2019-07-31
SG10201707487VA (en) 2017-10-30
IL241158A0 (en) 2015-11-30
PE20151990A1 (es) 2016-01-13
US20140275030A1 (en) 2014-09-18
HK1218650A1 (en) 2017-03-03
ES2909778T3 (es) 2022-05-10
SG11201506924YA (en) 2015-09-29
MX2015013149A (es) 2016-01-08
MX390039B (es) 2025-03-20
US9227985B2 (en) 2016-01-05
ZA201507255B (en) 2023-03-29
CN105164131B (zh) 2018-12-28
EA201591785A1 (ru) 2015-12-30
US11498926B2 (en) 2022-11-15
JP6529546B2 (ja) 2019-06-12
AU2014228175A1 (en) 2015-10-08
US20170210754A1 (en) 2017-07-27
US20180346481A1 (en) 2018-12-06
EA201992712A2 (ru) 2020-03-31
CN109593096B (zh) 2022-01-14
AU2014228175B2 (en) 2018-05-31
JP6712344B2 (ja) 2020-06-17

Similar Documents

Publication Publication Date Title
AR095326A1 (es) Heterociclos tricíclicos como inhibidores de la proteína bet
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
AR092742A1 (es) Piridinonas antifibroticas
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR096241A1 (es) Inhibidores de acc y usos de los mismos
AR109905A1 (es) Pirrolidinas sustituidas como moduladores de cftr
AR098721A1 (es) Inhibidores de biarilo de tirosina quinasa de bruton
AR096242A1 (es) Inhibidores de acc y usos de los mismos
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR088801A1 (es) Compuestos inhibidores de la fosfodiesterasa del tipo 10a
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR108207A1 (es) Derivados de pirrolo[2,3-c]piridina, inhibidores de bromodominios
AR088327A1 (es) Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
AR088328A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
BR112015018509A2 (pt) compostos de imidazo piridina
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR097325A1 (es) Pirroles anillados

Legal Events

Date Code Title Description
FG Grant, registration